Catalyst Pharmaceuticals, Inc.

NASDAQ:CPRX

Biotechnology

Healthcare
$31.49 -0.03%

-$0.01 today

Market cap
$3.85B
Beta
0.74
P/E (TTM)
17.3
EPS (TTM)
$1.81
52W Low $19.05High $32.56

Volume 0.00M

Average 2.17M

CPRX Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Catalyst Pharmaceuticals, Inc.NASDAQ: CPRX

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin grows, but more slowly than its trailing trend

Q1 FY2026 selling, general & admin of $49.32M rose 5.1% year over year, behind the +10.4% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 7.7% from the prior quarter. Over 3 fiscal years it compounded at +50.3% a year.

Context

  • Selling, general & admin amounted to 32.9% of revenue in FY2025, down 3.3 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 2 analysts of $208.97M (+7.9%) for the fiscal year ending Dec 2026, a slowdown from the +9.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$49.32M-7.7% QoQ
Last fiscal yearDec 2025
$193.75M+9.0% YoY
LTMMar 2026
$196.16M+10.4% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.1%+11.6%+6.4 pp
1 year+9.0%+7.9%-1.2 pp
3-year CAGR+50.3%+10.4%-39.9 pp
5-year CAGR+9.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
193.75M USD
Year-over-year change
+9.0%
4-year CAGR
+40.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How CPRX compares with its peers on the latest reported figures

  • CPRX's LTM Mar 2026 selling, general & admin of $196.16M is the 3rd highest of the 9 companies compared; the peer median is $165.89M.
  • Its year-over-year change of +10.4% is the 8th highest of 9, against a peer median of +22.1%.
  • Selling, general & admin amounts to 32.9% of revenue for CPRX, versus a peer median of 80.4%.
CPRX Competitors Peer median
Selling, General & Admin for CPRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KNSAKiniksa Pharmaceuticals, Ltd.LTM Jun 2026$230.9M +30.2%+26.1%27.5%
SRRKScholar Rock Holding CorporationLTM Sep 2026$198.39M +32.1%+60.5%34804.4%
CPRXCatalyst Pharmaceuticals, Inc.LTM Mar 2026$196.16M +10.4%+50.3%32.9%
AGIOAgios Pharmaceuticals, Inc.LTM Mar 2026$187.06M +11.8%+14.0%283.2%
ADPTAdaptive Biotechnologies CorporationLTM Jun 2026$180.38M +13.3%-3.2%58.5%
RXRXRecursion Pharmaceuticals, Inc.LTM Jun 2026$151.41M -30.0%+29.3%276.0%
BEAMBeam Therapeutics Inc.LTM Jun 2026$125.4M +14.0%+9.0%80.4%
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$69.2M +144.0%+94.7%—
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$69.19M +65.4%+42.7%30.7%
Peer median (excluding CPRX) $165.89M+22.1%+27.7%80.4%

Competitors are the stored peer set for CPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue140.83M214.2M398.2M491.73M588.99M
Cost of Revenue21.88M34.39M51.97M68.85M87.25M
Gross Profit118.95M179.81M346.24M422.89M501.74M
Gross Margin84.5%83.9%86.9%86.0%85.2%
Research & Development16.94M19.79M93.15M12.65M12.71M
Selling, General & Admin49.63M57.09M133.71M177.74M193.75M
Operating Expenses66.56M77.97M259.43M227.77M243.96M
Depreciation & Amortization192K1.24M32.88M37.77M37.87M
EBITDA52.86M105.96M127.39M254.04M321.39M
EBITDA Margin37.5%49.5%32.0%51.7%54.6%
Operating Income52.39M101.84M86.81M195.12M257.78M
Operating Margin37.2%47.5%21.8%39.7%43.8%
Interest Income00016.06M0
Interest Expense00000
Other Income / Expenses282K2.88M7.7M21.14M25.74M
Income Before Tax52.67M104.72M94.51M216.26M283.52M
Pre-Tax Margin37.4%48.9%23.7%44.0%48.1%
Income Tax Expense13.19M21.64M23.1M52.37M69.19M
Net Income39.48M83.08M71.41M163.89M214.33M
Net Margin28.0%38.8%17.9%33.3%36.4%
EPS (Basic)0.380.800.671.381.75
EPS (Diluted)0.370.750.631.311.68
Weighted Avg Shares103.38M103.37M106.28M118.46M122.29M
Weighted Avg Shares (Diluted)107.8M111.38M113.75M124.94M127.26M

Catalyst Pharmaceuticals, Inc.

NASDAQ:CPRX

Intrinsic Alpha fair value

Locked

Current Price

$31.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.